18H0 Stock Chart & Stats
€0.02
<€0.01(40.00%)
At close: 4:00 PM EDT
€0.02
<€0.01(40.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume10.00K
Average Volume (3M)8.48K
Market Cap
€9.94M
Enterprise Value€13.85
Total Cash (Recent Filing)€35.66K
Total Debt (Recent Filing)€4.84M
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding638,186,950
10 Day Avg. Volume1,450
30 Day Avg. Volume8,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug-delivery And Therapeutic Development PlatformA portfolio spanning therapeutic formulations and drug-delivery technologies gives the company multiple development pathways within health and life sciences. If successfully advanced, these programs could support product commercialization or intellectual-property licensing over the next several quarters.
Intellectual-property Monetization PotentialThe stated business model includes licensing or partnering drug-delivery technologies and therapeutic formulations, creating a potential route to monetize research without relying solely on direct product sales. This provides strategic optionality if development assets attract commercial partners.
Improved Asset BaseGrowth in total assets compared with prior years is a limited but tangible improvement in the balance-sheet base. If maintained alongside progress in the development portfolio, a larger asset base could provide more resources supporting research, partnerships, and eventual commercialization.
Bears Say
No Demonstrated Revenue TractionZero reported revenue across the available periods indicates that the business has not yet demonstrated commercial traction from its product candidates or technologies. Continued absence of sales leaves future funding dependent on development progress, partnerships, or other external sources.
Negative Equity And Excessive LeveragePersistent negative equity and debt that exceeds the asset base signal a weak capital structure and elevated solvency risk. This financial position limits flexibility to fund development internally and can increase dependence on financing, potentially constraining strategic choices.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the company is consuming cash rather than funding operations internally. The latest deterioration in free cash flow suggests funding requirements may be rising, increasing pressure to secure capital while products remain under development.
PreveCeutical Medical News
18H0 FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is €9.94M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Nov 19, 2026 which is in 54 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
PreveCeutical Medical Inc released its earnings results on Aug 28, 2026. The company reported -€0.001 earnings per share for the quarter.
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 638,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
PreveCeutical Medical Inc reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in DE:18H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―